Synergistic and antagonistic interactions of binary mixtures of polycyclic aromatic hydrocarbons in the upregulation of CYP1 activity and mRNA levels in precision-cut rat liver slices by Pushparajah, DS et al.
This is an author produced version of Synergistic and antagonistic interactions of binary 
mixtures of polycyclic aromatic hydrocarbons in the upregulation of CYP1 activity and 
mRNA levels in precision-cut rat liver slices.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/118393/
Article:
Pushparajah, DS, Plant, KE, Plant, NJ orcid.org/0000-0003-4332-8308 et al. (1 more 
author) (2017) Synergistic and antagonistic interactions of binary mixtures of polycyclic 
aromatic hydrocarbons in the upregulation of CYP1 activity and mRNA levels in 
precision-cut rat liver slices. Environmental Toxicology, 32 (3). pp. 764-775. ISSN 
1520-4081 
https://doi.org/10.1002/tox.22276
© 2016 Wiley Periodicals, Inc. This is the peer reviewed version of the following article: 
Pushparajah, D. S., Plant, K. E., Plant, N. J. and Ioannides, C. (2017), Synergistic and 
antagonistic interactions of binary mixtures of polycyclic aromatic hydrocarbons in the 
upregulation of CYP1 activity and mRNA levels in precision-cut rat liver slices. Environ. 
Toxicol., 32: 764–775. doi:10.1002/tox.22276; which has been published in final form at 
https://doi.org/10.1002/tox.22276. This article may be used for non-commercial purposes 
in accordance with the Wiley Terms and Conditions for Self-Archiving.
promoting access to
White Rose research papers
eprints@whiterose.ac.uk
http://eprints.whiterose.ac.uk/
Synergistic and antagonistic interactions of binary mixtures of polycyclic 
aromatic hydrocarbons in the upregulation of CYP1 activity and mRNA levels in 
precision-cut rat liver slices 
 
 
 
Daphnee S Pushparajah, Kathryn E Plant, Nick J Plant and Costas Ioannides 
 
Molecular Toxicology Group, Department of Biochemistry, Faculty of Health and 
Medical Sciences, University of Surrey, Guildford, Surrey, GU2 7XH, UK. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Short title: Interactions between Polycyclic Aromatic Hydrocarbons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corresponding author: Professor C Ioannides 
                                     Molecular Toxicology Group 
                                     Faculty of Health and Medical Sciences 
                                     University of Surrey 
                                     Guildford, Surrey 
                                     GU2 7XH, UK 
 
                                     Tel. No: +44 1483 689709 
                                     Fax No: +44 1483 686401 
                                     E-mail: c.ioannides@surrey.ac.uk 
 
 
 2 
Abstract 
The current studies investigate whether synergistic or antagonistic interactions in the 
up-regulation of CYP1 activity occur in binary mixtures of polycyclic aromatic 
hydrocarbons (PAHs) involving benzo[a]pyrene and five other structurally diverse 
PAHs of varying carcinogenic activity. Precision-cut rat liver slices were incubated 
with benzo[a]pyrene alone or in combination with a range of concentrations of a second 
PAH, and ethoxyresorufin O-deethylase, CYP1A1 and CYP1B1 mRNA levels 
determined. Concurrent incubation of benzo[a]pyrene with either 
dibenzo[a,h]anthracene or fluoranthene in liver slices led to a synergistic interaction, at 
least at low concentrations, in that ethoxyresorufin O-deethylase activity was 
statistically higher than the added effects when the slices were incubated with the 
individual compounds. In contrast, benzo[b]fluoranthene and, at high doses only, 
dibenzo[a,l]pyrene gave rise to antagonism, whereas 1-methylphenanthrene had no 
effect at all concentrations studied. When CYP1A1 mRNA levels were monitored, 
benzo[b]fluoranthene gave rise to an antagonistic response when incubated with 
benzo[a]pyrene, whereas all other compounds displayed synergism, with 1-
methylphenathrene being the least effective. A similar picture emerged when CYP1B1 
mRNA levels were determined, though the effects were less pronounced. In conclusion, 
it has been demonstrated that the benzo[a]pyrene-mediated upregulation of CYP1, at 
the mRNA and activity levels, is synergistically and antagonistically modulated by 
other PAHs. 
 
Keywords: Polycyclic aromatic hydrocarbons Ð Cytochrome P450 Ð Interactions Ð  
Risk assessment Ð Precision-cut tissue slices 
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Abbreviations 
PAH, Polycyclic Aromatic Hydrocarbon; Ah, Aryl hydrocarbon; Arnt, Aryl 
hydrocarbon nuclear translocator; D(a,l)P, Dibenzo[a,l]pyrene; 1-MP, 1-
Methylphenanhrene; B(a)P, Benzo[a]pyrene, F, Fluoranthene; B(b)F, 
Benzo[b]fluoranthene; D(a,h)A, Dibenzo[a,h]anthracene. 
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Introduction 
Polycyclic aromatic hydrocarbons (PAHs) comprise a major and ubiquitous class of 
chemical carcinogens to which humans are continuously exposed. The major sources 
of human exposure for the non-smoker are food, either as a result of atmospheric 
deposition from air or generation by cooking procedures such as barbecuing, and to a 
lesser extent air (Phillips, 1999); however, exposure may be much higher in individuals 
exposed to these compounds occupationally, for example those working in the coke 
industry and in steel plants (Seidel, 2004).  
PAHs are indirect carcinogens in that they require metabolic activation to 
genotoxic intermediates that are responsible for their carcinogenicity. Although at least 
three distinct metabolic pathways may generate such genotoxic intermediates, the 
principal ultimate carcinogens appear to be dihydrodiol epoxides (Luch and Baird, 
2004). An initial oxidation leads to the formation of primary epoxides which are then 
converted to dihydrodiols by epoxide hydrolase; a second oxidation produces the 
dihydrodiol epoxides. The CYP1 family of cytochromes P450, in particular CYP1A1 
and CYP1B1, is the dominant catalyst of both oxidation reactions (Shimada and Fujii-
Kuriyama, 2004; Ioannides and Lewis, 2004), but CYP3A4 can also catalyse the second 
oxidation (Shimada et al., 1989).  
Since the principal source of PAHs is the incomplete combustion of organic 
material, humans are exposed to complex mixtures of undefined composition rather 
than to individual compounds; carcinogenicity studies are, however, usually conducted 
using single pure compounds. Since PAHs display widely different carcinogenic 
activities, ranging from the highly carcinogenic to the non-carcinogenic, risk 
assessment of mixtures presents enormous difficulties as it is conceivable that a non-
carcinogenic component may act as a co-carcinogen by modulating the activity of a 
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carcinogen present in the same mixture. The default assumption used in the safety 
evaluation of PAH mixtures is that interactions between individual PAHs do not take 
place, and that carcinogenic risk can be evaluated by summation of the carcinogenic 
potencies of individual components or by using benzo[a]pyrene as the surrogate PAH 
(Relative Potency Factor, RLF) (Bostrom et al., 2002; Pufulete et al., 2004). However, 
the RLF approach in determining the carcinogenic risk from exposure to PAH mixtures 
may not reflect true carcinogenic potential, at least as far as skin cancer is concerned 
following topical exposure (Siddens et al., 2012). Bearing in mind that all PAHs share 
the same characteristics, in that they are all essentially planar compounds metabolised 
by the same cytochrome P450 enzymes through similar metabolic routes, it would not 
be unreasonable to anticipate interactions between components of a mixture. In fact, it 
has been documented that the cytochrome P450-catalysed metabolism of an individual 
PAH may be impaired by the presence of other PAHs (Shimada and Guengerich, 2006; 
Shimada et al., 2007); thus the carcinogenic potential of a PAH mixture may not be 
reflected by the carcinogenic activity of its individual components.  Indeed, studies 
conducted largely in the mouse skin model have shown that one PAH can markedly 
influence the carcinogenic activity of another, both synergistically and antagonistically, 
and such interactions are not necessarily the consequence of competitive inhibition of 
metabolism (Slaga et al., 1978; DiGiovanni et al., 1982). For example, the 
tumorigenicity of benzo[a]pyrene in the mouse skin model was elevated by its isomer 
benzo[e]pyrene whereas it was suppressed by dibenz[a,c]anthracene (DiGiovanni et al., 
1982). Similarly, a PAH-containing diesel exhaust matter that was non-tumorigenic in 
the mouse skin model interacted with other PAHs both synergistically and 
antagonistically (Courter et al., 2008). As similar interactions were noted in the extent 
of DNA adduct formation and bacterial mutagenicity, it is evident that PAH interactions 
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may occur at the initiation stage of carcinogenesis encompassing both the bioactivation 
of a carcinogen to its reactive intermediates and their subsequent binding to DNA (Rice 
et al., 1988; Hughes and Phillips, 1990; Smolarek et al., 1987; Lau and Baird, 1992; 
Marston et al., 2001; Cherng et al., 2001; Tarantini et al., 2011; Staal et al., 2007].  
An alternative site for PAH interactions is during binding to the aryl 
hydrocarbon (Ah) receptor, a transcription factor localised in the cytosol (Kohle and 
Bock 2009). There is increasing evidence that this receptor plays a pivotal role in 
chemical carcinogenesis (Safe et al., 2013; Feng et al., 2013). Indeed, Ah receptor null 
mice were refractive to the carcinogenicity of two of the most potent polycyclic 
aromatic hydrocarbons, namely benzo[a]pyrene and dibenzo[a,l]pyrene (Shimizu et al., 
2000; Nakatsuru et al., 2004). Moreover, experimental studies established that Arnt 
(aryl hydrocarbon receptor nuclear translocator), a protein that dimerizes with the Ah 
receptor prior to its interaction with DNA-response elements, is also required for 
tumour initiation by benzo[a]pyrene (Shi et al., 2009). 
In the present study we evaluated the potential of five, structurally diverse, 
PAHs to interact with benzo[a]pyrene, the prototypic and most extensively studied 
PAH, using the up-regulation of CYP1 as biomarker. The studies were performed using 
precision-cut rat liver slices, a convenient and far more preferable in vitro system than 
cancer cell lines and hepatocytes as it retains tissue architecture, cell composition and 
communication; the precision-cut tissue system, moreover, can be extended to human 
tissues (Ioannides 2013). We have already demonstrated that this system can be used 
to assess the potential of PAHs, in both liver and lung, to up-regulate CYP1 
(Pushparajah et al., 2007a) as well as other enzyme systems contributing to PAH 
metabolism (Pushparajah et al., 2007b). 
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Materials and methods 
 Materials 
Dibenzo[a,l]pyrene (D(a,l)P) 1-methylphenanthrene (1-MP) (LGC Promochem, 
Middlesex, UK), rat genomic DNA (Novagen, Wisconsin, USA), RNase-free DNase, 
cell culture lysis reagent, luciferase assay reagent (Promega, Wisconsin, USA), 
NADPH, benzo[a]pyrene (B(a)P), fluoranthene (F), benzo[b]fluoranthene (B(b)F), 
dibenzo[a,h]anthracene (D(a,h)A), ethoxyresorufin and resorufin (Sigma Co. Ltd., 
Poole, Dorset, UK), Qiagen RNeasy Mini kits (Crawley, West Sussex, UK), 
Absolute
TM
 QPCR Mix (Abgene, Epsom, Surrey, UK), and EarleÕs balanced salt 
solution (EBSS), foetal calf serum, gentamycin, hexamers, Superscript II and RPMI 
1640 with L-glutamine culture medium (Invitrogen, Paisley, Scotland) were all 
purchased. Twelve-well plates were obtained from Bibby Sterilin (Helena Biosciences, 
Sunderland, UK).  
 
Preparation and incubation of precision-cut tissue slices 
 Male Wistar albino rats (200g) were obtained from B&K Universal Ltd (Hull, East 
Yorkshire, UK). The animals were housed at 22 ± 2 ¡C, 30-40 % relative humidity in 
an alternating 12-hr light:dark cycle with light onset at 07.00 hr. Rats were killed by 
cervical dislocation, and liver was immediately excised.  
Liver slices (250 µm) were immediately prepared from 8mm cylindrical cores 
using a Krumdieck tissue slicer (Alabama Research and Development Corporation, 
Munsford, AL, USA) as previously described (Hashemi et al., 1999). The multiwell 
plate procedure, using 12-well culture plates, was used to culture the slices. One slice 
was placed in each well, in 1.5 ml of culture medium. Slices were incubated under 
sterile conditions on a reciprocating plate shaker housed in a humidified incubator, at a 
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temperature of 37 ¼C and under an atmosphere of 95 % air/5% CO2. The slices were 
initially pre-incubated for 30 min in order to slough off any dead cells due to slicing. 
Three different slice pools, comprising 10 slices, were used per time point. 
 
Enzyme assays 
Following incubation with the relevant PAHs, dissolved in DMSO (final concentration 
0.5% v/v), slices were removed from the medium, homogenised, and microsomal 
fractions were prepared by differential centrifugation. The O-deethylation of 
ethoxyresorufin (Burke and Mayer, 1974) and protein concentration (Bradford 1976) 
were determined in isolated microsomes.  
 
Transcript level measurement 
Two slices were used for total RNA extraction, and for each sample triplicate 
determinations were carried out. RNA was extracted using the Qiagen RNeasy Mini kit 
and was quantified using a Nanodrop spectrophotometer. Total RNA was treated with 
RNase-free DNase to remove genomic contamination. Reverse transcription was 
primed with random hexamers and carried out by Superscript II according to the 
manufacturerÕs instructions. To ensure that DNase-treated samples were free from 
genomic contamination, an RT- control was carried out for every RNA sample. cDNA 
generated from 50ng was amplified using Absolute
TM
 QPCR Mix with 400 nM primers 
and 100 nM fluorogenic probe in a total reaction volume of 25µl. Q-PCR reactions were 
run on the ABI7000 SDS instrument (Applied Biosystems, Warrington, UK) and 
quantitation was carried out using the ABI proprietary software against a standard curve 
generated from rat genomic DNA. 
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For the quantitative reverse transcription-polymerase chain reaction, the primer 
and TAMRA/FAM dual labelled probe  were designed using the Primer Express 
software (Applied Biosystems, CA,USA) to amplify sequences within a single exon, so 
that genomic DNA could be used as a standard (Pushparajah et al., 2007b), and were 
purchased from MWG (Ebersberg), Germany. 
 
Statistical evaluation 
Statistical evaluation was carried out using the Minitab package, version.14.0 
(MINITAB Inc., State. College, PA). Differences among mean values of sample groups 
were assessed by using the Ôleast significant differenceÕ (LSD) test.   
The equation for estimating the LSD is:   
2 2
)(
!=
t
t df n
s
LSD
 
where t(df) is the value of the t distribution for the degrees of freedom of MS.  The MS, 
mean squares for each source is simply the sum of squares divided by the degrees of 
freedom, s
2
 is the estimate of the pooled error MS from the analysis of variance and n 
is the sample size of the means. Enzyme activities are presented as percentage (%)-
change over control (slices incubated with DMSO, the vehicle, alone): ÔaddedÕ %-
change is the sum of %-change caused by benzo(a)pyrene and the second PAH when 
slices were incubated separately with either of these PAHs, whilst ÔcombinedÕ refers to 
the %-change caused by the change in activity after incubation of the liver slices with 
benzo(a)pyrene in combination with an additional PAH.  The possibility of an 
interaction caused by the binary mixture can then be obtained using the LSD value at 
each confidence level.  If the difference in the means of ÔaddedÕ and ÔcombinedÕ %-
change is greater than the LSD value, it can be inferred that the means are statistically 
different, and that the difference in activity caused by a mixture of the two PAHs is 
 10 
significantly different from an additive response, and due to an interaction effect.  LSD 
values were calculated for p < 0.05, <0.01 and <0.001. Expression of mRNA levels 
after incubation of rat liver slices with a combination of benzo(a)pyrene and another 
PAH were calculated as fold-change values.  These have been represented as Ôalteration 
from additivityÕ, i.e. the difference between the sum of ÔaddedÕ and ÔcombinedÕ fold-
change, and statistical testing was carried out once again utilising the least significant 
difference test.   
 
Results 
In an initial study, B(a)P caused a concentration-dependent increase in ethoxyresorufin 
O-deethylase (EROD) activity following incubation with liver slices for 24 hours 
(Figure 1). All subsequent studies employed concentrations of B(a)P (0.5 and 1 µM) 
that were far below the concentration eliciting maximum induction. 
When liver slices were incubated with a mixture of B(a)P and D(a,h)A, a 
synergistic interaction was noted in that the rise in EROD activity was statistically 
higher than the added effects observed when the slices were incubated with either of 
the chemicals alone, at all concentrations studied (Figure 2). More pronounced 
synergism was evident when F was co-incubated with B(a)P, but in this case it was 
confined to the lower F concentrations (Figure 3); no such effect was seen at the 10 µM 
or higher concentrations, and indeed antagonism was evident at the highest 
concentrations studied. In contrast, a marked antagonistic interaction was evident, at all 
concentrations studied, when a mixture of B(a)P and B(b)F was incubated with rat liver 
slices (Figure 4). When rat liver slices were incubated with a mixture of B(a)P and 
D(a,l)P, at the lower concentration of the former, no statistically significant interaction 
was observed (Figure 5); at the higher B(a)P concentration, however, and at the higher 
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concentrations of D(a,l)P a significant antagonistic interaction was seen. Finally, when 
the mixture of B(a)P and 1-MP was investigated, no interaction was seen at all 
concentrations studied (Figure 6). 
 In additional studies, rat liver slices were incubated with the same PAH binary 
mixtures in order to investigate the effect of the modulating PAH on the B(a)P-mediated 
up-regulation of CYP1A1 mRNA levels (Figure 7). When liver slices were exposed to 
B(a)P and D(a,h)A, at concentrations of the latter less than1 µM, a statistically 
significant synergistic increase in CYP1A1 mRNA levels was observed, i.e. the rise in 
mRNA levels in the liver slices exposed to the combination of PAHs was higher than 
the sum of the levels when slices were incubated with the individual PAHs (Figure 7B), 
but the effect was not visible at the higher concentrations of D(a,h)A. A similarly 
marked synergistic effect was evident when B(a)P was incubated concurrently with 
either D(a,l)P or F, at all concentrations studied (Figures 7A and 7D). A much more 
modest, but statistically significant, synergistic effect was noted when 1-MP served as 
the modulating hydrocarbon (Figure 7C). Finally, co-incubation of B(a)P with B(b)F, 
at all concentrations, resulted in a marked antagonistic effect, i.e. CYP1A1 mRNA 
levels in slices exposed to the combination of PAHs was much lower than the sum of 
the mRNA  levels when slices were incubated with the individual PAHs (Figure 7E). 
 A very similar picture emerged when CYP1B1 mRNA, instead of CYP1A1 
mRNA, levels were monitored, although the effects were less pronounced (Figure 8). 
D(a,h), at low concentrations, F, D(a,l)P and 1-MP displayed a statistically significant 
synergistic response when co-incubated with B(a)P, whereas an antagonistic response 
was seen in the case of B(b)F (Figure 8). 
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Discussion 
The precision-cut liver slice in vitro system was used to evaluate the potential of five 
structurally diverse PAHs to interact with B(a)P. Rat liver slices were incubated with 
B(a)P alone or in the presence of modulating PAHs for 24 hours, this being the 
incubation time required to achieve maximum induction of EROD, a reaction 
selectively catalysed by CYP1A1 (Namkung et al., 1988). Exposure of precision-cut 
rat liver slices to B(a)P (10 µM) led to a rise in EROD activity and CYP1A apoprotein 
levels that were most pronounced at 24-hours; a rise in CYP1A1 mRNA levels was 
evident as early as 4-hours post-incubation but no change in EROD activity or CYP1A 
apoprotein levels were noted at this time point (Pushparajah et al., 2207b). Similar 
observations were made using non-PAH CYPIA inducers such as the glucosinolates 
glucoerucin and glucoraphanin (Abdull Razis et al., 2012). In an initial study, B(a)P 
was shown to cause a concentration-dependent rise in EROD activity, and two low 
concentrations, 0.5 and 1.0 µM, were utilised in subsequent studies as they do not cause 
near maximal induction of this enzyme. Similarly, the choice of concentrations of the 
modulating PAHs was chosen based on our previous studies in which the potential of 
each PAH to elevate EROD activity was evaluated following similar incubations with 
rat liver slices for 24 hours (Pushparajah et al., 2007a). Consequently, lower 
concentrations were used in the case of B(b)F and D(a,h)A that are potent EROD 
inducers, whereas a higher range of concentrations was employed in the case of F, 
D(a,l)P and 1-MP which are either very weak or non-inducers. Indeed, the current 
studies confirm our previous findings that B(b)F and D(a,h)A are the most potent 
inducers of EROD activity in rat slices, whereas 1-MP is completely inactive 
(Pushparajah et al., 2007a). 
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 The B(a)P-mediated rise in EROD activity was synergistically increased by 
D(a,h)A and F whereas it was antagonised by B(b)F, and no effect was evident in the 
case of 1-MP; antagonism was also observed at high concentrations of D(a,l)P, but was 
confined to the higher of the two B(a)P concentrations used. Clearly, these studies 
demonstrate that PAHs in binary mixtures have the potential to interact, both in a 
synergistic or antagonistic manner. Of relevance is the fact that interactions in the 
present study occurred primarily at low concentrations, circa 1µM, of the interacting 
PAHs.  Such interactions have also been reported in the trout following exposure to 
individual and mixtures of PAHs and determination of EROD activity (Basu et al., 
2001). In rat hepatoma H4IIE cells, co-incubation of benzo[a]pyrene with fluoranthene, 
both at 10 µM, resulted in a rise in B(a)P-DNA adducts commensurate with the present 
findings (Willett et al., 1998). Similarly, fluoranthene enhanced B[a]P-DNA adduct 
formation in mouse skin (Rice et al., 1984). Finally, fluoranthene increased the number 
of tumours when applied with benzo[a]pyrene in mouse skin (Van Duuren and 
Goldschmidt, 1976). 
Fluoranthene, at high doses only (50 and 100 µM), gave rise to antagonism; this 
is unlikely to be due to loss of liver slice viability as none of these PAHs, at the 
concentrations studied, caused any toxicity as exemplified by the leakage of lactic acid 
dehydrogenase (results not shown). It is more likely that at these high concentrations 
fluoranthene suppresses the CYP1-mediated O-deethylation of ethoxyresorufin directly 
or through mechanism-based inhibition as already established using the human 
orthologous enzymes (Shimada and Guengerich, 2006; Shimada et al., 2007). In these 
studies fluoranthene inhibited the CYP1B1-mediated EROD with an IC50 0.013 µM 
(Shimada and Guengerich, 2006). These data are also consistent with previous reports 
where high concentrations (20 µM) of fluoranthene inhibited the 2,3,7,8-
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tetrachlorodibenzo-p-dioxin (TCDD)- and benzo[k]fluoranthene-induced EROD 
activity in rat hepatoma H4IIE cells (Willett et al., 1998). As no changes at the mRNA 
or protein levels were evident in the same study, it may be cautiously inferred that 
CYP1 inhibition is the responsible mechanism. It has already been reported that that 
the DNA-binding of PAHs in human MCF-T cells could be suppressed by a mixture of 
PAHs extracted from coal tar (Standard Reference Material 1597) as a result of 
inhibition of  CYP1A1 and CYP1B1 responsible for their bioactivation (Mahadevan et 
al., 2007).  
To establish whether similar interactions occurred at the level of transcription, 
liver slices were incubated for 24 hours with B(a)P alone or in combination with the 
other PAHs, and CYP1A1 mRNA levels monitored. All PAHs caused a synergistic 
increase in CYP1A1 mRNA levels when co-incubated with B(a)P, at least at the low 
concentrations; the only exception was B(b)F, which led to an antagonistic response at 
all concentrations studied. These studies imply that interactions between PAHs may 
occur at the level of transcription , with non-additive changes in mRNA expression 
being consistent with the non-additive changes in EROD expression observed. D(a,l)P 
also interacted synergistically at the CYP1 mRNA level, although weakly compared 
with the other PAHs, despite the antagonism observed at high concentrations when 
EROD activity was monitored. A possible explanation is that in this case the 
antagonistic interaction reflects inhibition of CYP1 activity, rather than a 
transcriptional event. We note that D(a,l)P displayed no inhibition of EROD activity 
catalysed by human CYP1 enzymes at concentrations up to 1 µM (Shimada and 
Guengerich, 2006), consistent with our observation of no effect until D(a,l)P 
concentrations exceeded10 µM. Finally,  1-MP also synergistically increased CYP1A1 
mRNA levels when co-incubated with B(a)P in liver slices, but the effect was much 
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less pronounced compared with the other PAHs studied, and was not reflected in 
concurrent changes in EROD activity. It is pertinent to point out that the existence of 
threshold levels has been proposed that must be exceeded in order for mRNA to be 
translated, hence activation of the gene at the mRNA level does not always lead to 
higher protein levels, and concords with the data presented herein (Greenbaum et al., 
2003).  
 As no validated chemical probe selective for CYP1B1 is currently available, no 
studies were undertaken at the activity level. Although CYP1B1 apoprotein can be 
detected in rat liver, albeit at much lower levels compared with lung (Pushparajah et 
al., 2007a), this was not possible in liver slices following a 24-hour incubation, 
presumably because of the decline in cytochrome P450 expression that occurs during 
the incubation of liver slices (Hashemi et al., 2000). Consequently, studies were 
confined to the mRNA level. A similar picture emerged as in the case of CYP1A1, in 
that the B(a)P-mediated elevation of CYP1B1 mRNA levels was suppressed by B(b)F 
but synergistically elevated with the other PAHs studied. As noted in our previous 
studies in rat liver, CYP1B1 mRNA levels were lower and less inducible by PAHs 
compared with CYP1A1 (Pushparajah et al., 2007a). 
 As the induction of the CYP1 family of enzymes is regulated by the Ah receptor, 
the possibility arises that these interactions occur during the binding and/or activation 
of this receptor to DNA ligand-binding form; this receptor is important in the 
bioactivation of PAHs although Ah-independent pathway(s) appear also to exist 
(Sagredo et al., 2009). The fact that these interactions were also evident at the 
CYP1A1/IB1 mRNA level concords with an involvement of the Ah receptor, and 
synergistic interactions of PAH mixtures through Ah activation have been reported 
previously (Choulapka et al., 1993; Cherng et al., 2001). It has already been reported 
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that benzo[g,h,i]perylene increased the B[a]P-mediated CYP1A1 transcription in 
HepG2 cells as well as B[a]P DNA adducts (Cherng et al., 2001). Similarly, some 
aromatic amines were shown to interact synergistically with B(a)P in the transcription 
of Ah receptor-dependent genes (Borza et al., 2008). It is worthwhile to point out that 
1-MP, which failed to interact with B(a)P, is not a ligand for this receptor, whereas 
B(b)F, the only compound that antagonised B(a)P in the present study, is also the only 
PAH that has higher affinity than B(a)P for this receptor  (Pushparajah et al., 2007a). 
However, for firm conclusions to be drawn as to the relationship between Ah agonist 
activity and the nature of the interaction, additional studies are necessary employing a 
larger number of compounds and preferably human precision-cut liver slices. 
Interaction studies utilising binary mixtures of B(a)P and 7H-dibenzo[c,g]carbazole, a 
heterocyclic aromatic hydrocarbon, revealed the rat and human cells respond 
differently (Gbelov et al., 2013) indicating that robust risk assessments should be 
biased toward human-derived data. Moreover, it is logical to envisage that the 
carcinogenicity of PAHs in mixtures is unlikely to reflect solely interactions between 
parent compounds but is likely to also involve their metabolic products. For example, 
metabolites such as mono- and dihydroxy-metabolites of PAHs may be potent inducers 
of the CYP1 family suggesting that they are agonists of the Ah receptor (Spink et al., 
2008; Gbelov et al., 2013). Similarly, they can be potent inhibitors of CYP1 activity 
(Shimada and Guengerich, 2006).  
Finally, no apparent relationship is evident between carcinogenic potency of 
individual PAHs and the nature of the interaction. D(a,h)A, B(b)F and, in particular, 
D(a,l)P are carcinogenic chemicals; however, the first caused a synergistic interaction 
with B(a)P whereas the latter two displayed antagonism under the same conditions. 
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Similarly F and 1-MP are considered to be weak or non-carcinogens; the former gave 
rise to a synergistic interaction whereas the latter had no such effect. 
The formation of the dihydrodiol epoxide of B(a)P, the ultimate carcinogen, 
involves initially an oxidation catalysed by the cytochrome P450 system to generate 
primary epoxides, the levels of which are modulated by epoxide hydrolase, which 
converts the primary epoxides to the dihydrodiol, and glutathione S-transferase, which 
detoxifies both the primary and dihydrodiol epoxides. While both of these systems are 
inducible by a number of PAHs including B[a]P, it is to a much lesser extent compared 
with CYP1 (Pushparajah et al., 2008a and b). Consequently, it is likely that the CYP-
mediated epoxide formation will exceed its safe removal, thus amplifying intracellular 
epoxide levels. It is pertinent to point out that no statistically significant interactions 
were observed at the activity level when the same binary mixtures were incubated with 
rat liver slices under the same conditions and epoxide hydrolase was monitored with 
benzo[a]pyrene 4,5-oxide as the substrate, and glutathione S-transferase using 7-chloro-
4-nitrobenzo-2-oxa-1,3-diazole as substrate (results not shown), indicating that 
interactions are confined to CYP1 expression. This raises the possibility that synergistic 
interactions at the level of CYP1 induction may be further exacerbated due to a lack of 
a similar synergistic response in the detoxification systems. 
 The current studies employing binary mixtures have shown the potential of 
PAHs, at low concentrations, to interact both in synergistic and antagonistic manner in 
the up-regulation of CYP1; it would be desirable to extend these studies to ascertain 
whether such interactions lead to concomitant changes in the levels of DNA adducts. 
Thus this approach employing precision-cut liver slices may prove helpful in assessing 
the potential of PAH mixtures to elicit DNA damage, although more extensive studies 
to validate and underpin this procedure would be indispensable. A good correlation 
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appears to exist for PAHs between the level of DNA adducts and carcinogenic potential 
(Phillips 2005), and while contradictory observations have also been reported (Siddens 
et al., 2012), it could be cautiously inferred that interactions will impact on the 
carcinogenicity of mixtures. It is imperative that studies are also conducted in precision-
cut human liver slices to establish whether the same antagonistic/synergistic  
interactions occur as seen in the rat; it is pertinent to point out that when human and rat 
precision-studies were exposed to various PAHs, under identical conditions, the same 
profile in CYP1A1 up-regulation was noted (Pushparajah et al 2007a).Furthermore, it 
would be logical to envisage that interactions between PAHs are likely to also occur at 
post-initiation stages. Indeed in recent studies (Huang et al., 2012), F was shown to 
increase the B(a)P-induced expression of p53, a tumour suppressor gene. 
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Figure 1: Induction of ethoxyresorufin O-deethylase (EROD) activity by 
benzo[a]pyrene [B(a)P] in precision-cut rat liver slices 
 
Rat liver slices were incubated with a range of benzo[a]pyrene concentrations (0 Ð 10 
µM) for 24 hours, and EROD activity was determined in the microsomal fraction.  
Results are presented as mean ± SD where n = 3 slices, from five pooled livers.  *: p < 
0.05, **: p < 0.01 and ***: p < 0.001. 
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Figure 2: Effect of dibenzo(a,h)anthracene [D(a,h)] on B(a)P-mediated EROD 
activity precision-cut rat liver slices 
Rat hepatic slices were incubated with either (a) 0.5 or (b) 1.0 µM B(a)P and a range of 
D(a,h)A concentrations (0 Ð 0.25 µM) for 24 hours, and EROD activity was determined 
in the microsomal fraction.  The figure represents the activities as %-change where 
activities of control slices (incubated with the vehicle alone) correspond to 100%.  
Results are presented as mean ± SD where n = 3 slices, from five pooled livers.  LSD 
value = 11.69 at p < 0.001 (***), when compared with the sum of %-change in activities 
of slices incubated with the corresponding concentration of B(a)P and PAH alone. 
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Figure 3: Effect of fluoranthene [F] on B(a)P-mediated EROD activity in 
precision-cut rat liver slices 
Rat hepatic slices were incubated with either (a) 0.5 or (b) 1.0µM B(a)P and a range of 
F concentrations (0 Ð 100 µM) for 24 hours, and EROD activity was determined in the 
microsomal fraction.  The figure represents the activities as %-change where activities 
of control slices (incubated with the vehicle alone) correspond to 100%.  Results are 
presented as mean ± SD where n = 3 slices, from five pooled livers.  LSD values = 0.79 
at p < 0.01 (**) and 0.95 at p < 0.001 (***), when compared with the sum of %-change 
in activities of slices incubated with the corresponding concentration of B(a)P and PAH 
alone. 
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Figure 4: Effect of benzo(b)fluoranthene [B(b)F] on B(a)P-mediated EROD 
activity in precision-cut rat liver slices 
Rat hepatic slices were incubated with either (a) 0.5 or (b) 1.0 µM B(a)P and a range of 
B(b)F concentrations (0 Ð 1 µM) for 24 hours, and EROD activity was determined in 
the microsomal fraction.  The figure represents the activities as %-change where 
activities of control slices (incubated with the vehicle alone) correspond to 100%.  
Results are presented as mean ± SD where n = 3 slices, from five pooled livers.  LSD 
values = 17.68 at p < 0.01 (**) and 23.22 at p < 0.001 (***), when compared with the 
sum of %-change in activities of slices incubated with the corresponding concentration 
of B(a)P and PAH alone 
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Figure 5: Effect of dibenzo(a,l)pyrene [D(a,l)P] on B(a)P-mediated EROD activity 
in precision-cut rat liver slices 
Rat hepatic slices were incubated with either (a) 0.5 or (b) 1.0 µM B(a)P and a range of 
D(a,l)P concentrations (0 Ð 100 µM) for 24 hours, and EROD activity was determined 
in the microsomal fraction.  The figure represents the activities as %-change where 
activities of control slices (incubated with the vehicle alone) correspond to 100%.  
Results are presented as mean ± SD where n = 3 slices, from five pooled livers.  LSD 
value = 2.45 at p < 0.001 (***), when compared with the sum of %-change in activities 
of slices incubated with the corresponding concentration of B(a)P and PAH alone.    
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Figure 6: Effect of 1-methylpyrene [1-MP] on B(a)P-mediated EROD activity in 
precision-cut rat liver slices 
Rat hepatic slices were incubated with either (a) 0.5 or (b) 1.0 µM B(a)P and a range of 
1-MP (0 Ð 100 µM) for 24 hours, and EROD activity was determined in the microsomal 
fraction.  The figure represents the activities as %-change where activities of control 
slices (incubated with the vehicle alone) correspond to 100%.  Results are presented as 
mean ± SD where n = 3 slices, from five pooled livers.   
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Figure 7: CYP1A1 mRNA levels following incubation of rat liver slices with B(a)P 
and other PAHs alone or in combination 
Rat hepatic slices were incubated in the presence of either 0.5 or 1.0 µM B(a)P and a 
range of concentrations of B(b)F (0 Ð 5 µM), D(a,h)A (0 Ð 10 µM) or F, D(a,l)P and 1-
MP (0-100 µM) for 24 hours.  Total RNA was extracted from whole liver slices, and 
levels of CYP1A1 mRNA were determined by quantitative RT-PCR methodology 
(TaqMan).  Alteration from additivity of fold-change in CYP1A1 mRNA levels is 
shown and results are presented as mean ± SD where n = 4 slices, from five 
pooled livers.  LSD values = 57.4 at p < 0.01 (**) for D(a,h)A, 46.5 at p < 0.05 (*) and 
57.6 at p < 0.01 (**) for D(a,l)P, 57.1 at p < 0.01 (**) for F, 32.7 at p < 0.05 (*) and 
44.3 at p < 0.01 (**) for 1-MP and 46.9 at p < 0.01 (**) for B(b)F, when compared with 
the sum of %-change in activities of slices incubated with the corresponding 
concentration of B(a)P and the other PAH alone.    
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Figure 8: CYP1B1 mRNA levels following incubation of rat liver slices with B(a)P 
and other PAHs alone or in combination.   
Rat hepatic slices were incubated in the presence of either 0.5 or 1.0 µM B(a)P and a 
range of concentrations of B(b)F (0 Ð 5 µM), D(a,h)A (0 Ð 10 µM) or F, D(a,l)P and 1-
MP (0-100 µM) for 24 hours.  Total RNA was extracted from whole liver slices, and 
levels of CYP1B1 mRNA were determined by quantitative RT-PCR methodology 
(TaqMan).  Alteration from additivity of fold-change in CYP1B1 mRNA levels is 
shown and results are presented as mean ± SD where n = 4 slices, from five 
pooled livers.  LSD values = 11.3 at p < 0.05 (*) for D(a,h)A, 7.3 at p < 0.05 (*) for 
D(a,l)P, 8.1 at p < 0.05 (*) for F, 3.0 at p < 0.01 (**) for 1-MP and 2.4 at p < 0.05 (*) 
for B(b)F, when compared with the sum of %-change in activities of slices incubated 
with the corresponding concentration of B(a)P and the other PAH alone.    
 
 
 
